Qwen3’s open-weight release under an accessible license marks an important milestone, lowering barriers for developers and organizations.

For patients with cancers harboring certain genetic defects, the first-in-class targeted therapy RO7589831, which targets the ...

Sexually transmitted infections (STIs) result in millions of cases and cost over $16 billion annually in the U.S. High asymptomatic rates and stigma hinder timely diagnosis and elimination efforts.